More cancer drugs to become cheaper
Print Edition
China will make more cancer drugs affordable, as a new round of negotiations between the state medical insurance administration and pharmaceutical companies to add such drugs to the medical insurance list is scheduled to finish by the end of September.
The administration said it has selected a range of drugs to be added and is confirming the producers’ willingness to negotiate further.
All these drugs are of great clinical value and will bring huge benefits to patients with cancers or tumors, including colorectal cancer, renal cell carcinoma, lymphoma, and chronic myelogenous leukemia, said the administration.
China has exempted import tariffs from all common drugs, including cancer drugs, cancer alkaloid-based drugs, and imported traditional Chinese medicine since May 1.
Based on the new policy, 12 pharmaceutical companies have recalculated the prices of their products and will submit applications for price adjustments as per the administration’s requirement.
Talks launched in 2017 led to the lowering of prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib. They were also added to the medical insurance reimbursement list.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
